What Is Pneumococcal Disease? | What Is the Pneumococcal Vaccine? | Who Should Get Vaccinated and When? | What Are the Risks Associated With the Pneumococcal Vaccine? | Who Should Not Get Vaccinated? | What Other Ways Can Pneumococcal Disease Be Prevented Besides Vaccination? | What Happens in the Event of an Outbreak?

Who Should Get Vaccinated and When?

The PPSV is given to adults aged 65 and older.

PPSV is also given to anyone aged 2 to 64 who has certain conditions, such as:

PPSV is also given to anyone aged 2 to 64 who is taking a drug or treatment that lowers the body's ability to resist infection, such as:

  • Long-term steroids
  • Certain cancer drugs
  • Radiation therapy

The vaccine should be given at least 2 weeks before cancer treatment begins.

PPSV should also be given to any adult aged 19 to 64 years old who:

  • Is a smoker
  • Has asthma
  • Having certain conditions, such as:
  • Taking medicine that suppresses the immune system

In some cases, a second dose of PPSV may be needed. For example, another dose after five years may be needed for people aged 19-64 years who have conditions like chronic renal failure or HIV/AIDS. A second dose is also recommended at age 65 for people who received a dose previously

References:

Baker CJ, Pickerling LK, Chilton L, et al; Advisory Committee on Immunization Practices. Recommended adult immunization schedule: United States, 2011. Ann Intern Med. 1 Feb 2011. 154(3):168-173.

Centers for Disease Control and Prevention. Recommended immunization schedules for persons aged 0-18 years —United States, 2012. MMWR 2012;61(5).

Pneumococcal conjugate vaccine. Centers for Disease and Control and Prevention website. Available at: http://www.cdc.gov/vaccines/pubs/vis/downloads/vis-pcv.pdf. Update April 16, 2010. Accessed December 12, 2012.

Pneumococcal polysaccharide vaccine. Centers for Disease Control and Prevention website. Available at: http://www.cdc.gov/vaccines/pubs/vis/downloads/vis-ppv.pdf. Updated October 2009. Accessed December 12, 2012.

Pneumococcal: understanding the disease. National Network for Immunization Information website. Available at: http://www.immunizationinfo.org/vaccines/pneumococcal-disease. Updated March 31, 2010. Accessed December 12, 2012.

Recommended adult immunization schedule—United States, 2012. MMWR Morb Mortal Wkly Rep. 2012;6(4). Centers for Disease Control and Prevention website. Available at: http://www.cdc.gov/vaccines/schedules/downloads/adult/mmwr-adult-schedule.pdf. Accessed December 12, 2012.

Vaccine information for the public and health professionals—pneumoccocal vaccine: questions and answers. Immunization Action Coalition website. Available at: http://www.vaccineinformation.org/pneumchild/qandavax.asp. Updated November 2012. Accessed December 12, 2012.

Vaccine information statement: pneumococcal conjugate vaccine. Centers for Disease Control and Prevention website. Available at: http://www.cdc.gov/vaccines/pubs/vis/downloads/vis-pcv.pdf. Updated April 16, 2010. Accessed December 12, 2012.

1/31/2008 DynaMed's Systematic Literature Surveillance http://www.ebscohost.com/dynamed/what.php: Centers for Disease Control and Prevention. Recommended immunization schedules for persons aged 0-18 years—United States, 2008. MMWR. 2008;57;Q1-Q4. Centers for Disease Control and Prevention, MMWR website. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5701a8.htm. Updated January 10, 2008. Accessed January 28, 2008.

10/30/2009 DynaMed's Systematic Literature Surveillance http://www.ebscohost.com/dynamed/what.php: Prymula R, Siegrist C, Chlibek R, et al. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. Lancet. 2009;374(9698):1339.

9/17/2010 DynaMed's Systematic Literature Surveillance http://www.ebscohost.com/dynamed/what.php: Centers for Disease Control and Prevention. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep. 2010;59(34):1102-1106.

1/7/2011 DynaMed's Systematic Literature Surveillance http://www.ebscohost.com/dynamed/what.php:

Nuorti J, Whitney C, Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease among infants and children—use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine. MMWR Morb Mortal Wkly Rep. 2010;59(34):1102.

Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep. 2010;59(34):1102-1106.

Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices. Licensure of a 13-Valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children. MMWR Recomm Rep. 2010;59(RR-11):1.

Last reviewed December 2012 by Brian Randall, MD

Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.